From: The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
4 | N (%) |
Age median (range) | Median survival years (95% CI) | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p Value | Hazard ratio | 95% CI | p Value | ||||
Group 4 | |||||||||
AA, IDH-wildtype | 15 | 51 (26–72) | 18.1 (0.000–36.278) | ||||||
TERTp-mutant | 3 | 69.0 (62–72) | 8.0 (0.000–20.002) | 0.341 | 0.85–1.377 | 1.113 | 1.11 | 0.116–10.608 | 0.928 |
TERTp-wildtype | 12 | 46.5 (27–58) | 18.1 (0.000–46.107) | ||||||
ATRX-mutant | 9 | 44.5 (27–69) | 28.2 (0.954–55.446) | 0.555 | 0.182–1.687 | 0.299 | 0.731 | 0.214–2.498 | 0.618 |
ATRX-wildtype | 6 | 54 (41–72) | 11.7 (6.733–16.667) | ||||||
MGMTp-methylated | 8 | 48.5926–62) | 28.2 (18.448–37.952) | 1.109 | 0.365–3.367 | 0.856 | 1.076 | 0.261–4.434 | 0.919 |
MGMTp-unmythylated | 7 | 54 (27–72) | 7.9 (2.218–13.582) | ||||||
Age < 55 years old | 10 | 41.5 (26–54.9) | 28.2 (8.676–47.724) | 4.027 | 1.048–15.472 | 0.043 | 0.296 | 0.042–2.107 | 0.224 |
Age > 55 years old | 5 | 62 (57–69) | 8.0 (7.785–8.215) | ||||||
Group 5 | |||||||||
GBM, IDH-wildtype | 52 | 55 (17–79) | 14.5 (10.378–18.622) | ||||||
TERTp-mutant | 41 | 58 (36–79) | 16.4 (13.012–19.516) | 0.768 | 0.390–1.513 | 0.445 | 2.111 | 1.016–4.389 | 0.045 |
TERTp-wildtype | 11 | 42 (31–69) | 13.0 (1.021–25.039) | ||||||
ATRX-mutant | 5 | 58 (29–69) | 13.0 (0.513–25.547) | 0.682 | 0.269–1.733 | 0.422 | 1.269 | 0.499–3.231 | 0.617 |
ATRX-wildtype | 47 | 55 (31–79) | 16.4 (12.773–20.027) | ||||||
MGMTp-methylated | 26 | 57.5 (29–79) | 18.3 (12.671–23.989) | 0.579 | 0.326–1.031 | 0.061 | 0.665 | 1.399–5.078 | 0.002 |
MGMTp-unmythylated | 26 | 51 (36–79) | 13.0 (9.407–16.653) | ||||||
Age < 55 years old | 24 | 45 (29–54.9) | 20.8 (13.599–28.001) | 1.843 | 1.047–3.331 | 0.035 | 3.090 | 1.578–6.049 | 0.001 |
Age > 55 years old | 28 | 67 (55.3–79) | 10.5 (5.703–15.297) |